Jumonji Domain-Containing Protein 4 (JMJD4) Antibody

Covalent modification of histones plays critical role in regulating chromatin structure and transcription. While most covalent histone modifications are reversible, only recently has it been established that methyl groups are subject to enzymatic removal from histones. A family of novel JmjC domain-containing histone demethylation (JHDM) enzymes have been identified that perform this specific function. Histone demethylation by JHDM proteins requires cofactors Fe (II) and alpha-ketoglutarate. Family members include JHDM1 (demethylating histone 3 at lysine 36), and JHDM2A as well as JMJD2CH3K9 (both of which demethylate histone 3 at lysine 9). Contributions of histone demethylase activity to tumor development, decreases in cell proliferation, and hormone-dependent transcriptional activation have been observed.

Target	Jumonji Domain-Containing Protein 4 (JMJD4)
Clonality	Polyclonal
Reactivity	Human
Tested Applications	ELISA, WB
Host	Rabbit
Recommended dilutions	WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Immunogen	KLH-conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human JMJD4.
Isotype	IgG
Form	Liquid
Purification	Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC	Q9H9V9 (UniProt, ExPASy)
UniProt Secondary AC	Q5TBZ1, Q5TBZ6, Q9H970
UniProt Entry Name	JMJD4_HUMAN
String	9606.ENSP00000355720
Molecular Weight	Calculated MW: 52.5 kDa
Buffer	PBS containing 0.09% sodium azide.
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on Jumonji Domain-Containing Protein 4 (JMJD4)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue